No Data
No Data
Monte Rosa Therapeutics Presents Preclinical Data at AACR on MRT-51443
Express News | Monte Rosa's MRT-51443 Demonstrates Potent CDK2 Degradation And Delays Resistance To CDK4/6 Inhibitors In Preclinical Studies
Monte Rosa Therapeutics Insider Ups Holding During Year
Insider Purchase: Director at $GLUE Buys 10,000 Shares
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $20
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $19